51st week of 2021 patent applcation highlights part 10 |
Patent application number | Title | Published |
20210393710 | METHOD FOR MANUFACTURING WATER-IN-OIL-IN-WATER MULTIPLE EMUSION - The present invention provides a method for manufacturing a water-in-oil-in-water multiple emulsion, comprising: (a) mixing an active component with an internal aqueous phase to form a homogenized mixture; (b) mixing the homogenized mixture with an oleaginous phase to form a water-in-oil emulsion; and (c) mixing the water-in-oil emulsion with an external aqueous phase to form the water-in-oil-in-water multiple emulsion, wherein the external aqueous phase comprises water and an excipient, and wherein the excipient comprises a whey protein concentrate and a modified starch. | 2021-12-23 |
20210393711 | BACTERIA EXPRESSING SINGLE CHAIN ANTIBODIES AGAINST TOLL-LIKE RECEPTORS - The present invention provides transgenic bacteria capable of secreting single chain antibodies and antibody fragments directed to Toll-Like Receptors. Compositions comprising the transgenic bacteria and method of preventing and treating infectious, inflammatory and proliferative conditions are also provided. | 2021-12-23 |
20210393712 | Probiotic Supplement For Metabolic Health - The application discloses | 2021-12-23 |
20210393713 | COMPOSITIONS AND METHODS USEFUL FOR TARGETING THE BLOOD-BRAIN BARRIER - Compositions and methods for delivering effector entities to the CNS of a subject are provided. Engineered AAV capsids that bind GPI-anchored proteins on the BBB are provided as well as methods for their use, including delivery of gene therapy and effector entities. Also provided, are methods for reducing the infectivity of the CNS by an AAV. | 2021-12-23 |
20210393714 | Modulation of AAV Vector Transgene Expression - Aspects of the invention relate to recombinant adeno-associated viruses (rAAVs). In some aspects, the rAAVs comprise artificial genetic regulatory elements that modulate transgene expression. In some aspects, the disclosure relates to the treatment of lysosomal storage disorders. | 2021-12-23 |
20210393715 | ANTI-CANCER-ASSOCIATED NON-TUMOR CELL AGENT COMPRISING VIRUS - In one embodiment, the present invention provides an anti-cancer-associated non-tumor cell agent. | 2021-12-23 |
20210393716 | METHODS AND COMPOSITIONS COMPRISING PSYCHOACTIVE COMPOUNDS FROM PSYCHOACTIVE ORGANISMS - This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids. | 2021-12-23 |
20210393717 | METHODS AND COMPOSITIONS COMPRISING PSYCHOACTIVE COMPOUNDS FROM PSYCHOACTIVE ORGANISMS - This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids. | 2021-12-23 |
20210393718 | Methods of Extraction of Plant Materials and Extracts Obtained Using Supercritical Glycerin - A method for extracting bioactive compounds from plant materials using supercritical glycerin and at least one inert co-solvent that lowers the effective supercritical point of the supercritical glycerin to its boiling point, and the extracts obtained from the method. | 2021-12-23 |
20210393719 | POWDERED BOTANICAL EXTRACT PREPARATIONS AND FORMULATIONS THEREOF - The present invention provides a powdered botanical extract preparation comprising an evenly distributed dispersion of a botanical extract in a methylsulfonylmethane matrix, processes for preparing the preparations, and dosage forms comprising the preparations. | 2021-12-23 |
20210393720 | Hair Growth Compositions - The present application provides hair growth compositions, and more particularly compositions comprising | 2021-12-23 |
20210393721 | COMPOSITIONS COMPRISING DEAD SEA EXTRACT AND AN EXTRACT OF APPLE OF SODOM AND USES THEREOF - Provided are compositions including at least one Dead Sea extract and at least one extract of the Apple of Sodom ( | 2021-12-23 |
20210393722 | COMPOSITION FOR IMPROVING SKIN BARRIER DAMAGE AND/OR ALLEVIATING SKIN INFLAMMATION, CONTAINING 3,5-DICAFFEOYLQUINIC ACID AS ACTIVE INGREDIENT - The present invention relates to a composition for improving skin barrier damage and/or alleviating skin inflammation, wherein 3,5-dicaffeoylquinic acid isolated from an | 2021-12-23 |
20210393723 | COMPOSITION FOR PHOTODYNAMIC REACTION CONTAINING EXTRACT OF LIGULARIA FISCHERI AS AN EFFECTIVE INGREDIENT, ANTIMICROBIAL, ANTIFUNGAL AND STERILIZATION COMPOSITION INCLUDING THE SAME, AND STERILIZATION METHOD USING THE COMPOSITION FOR PHOTODYNAMIC REACTION - Provided are methods of reducing and killing bacteria and fungi, and photodynamic treatment methods and sterilization methods using the methods of reducing and killing bacteria and fungi. The method of reducing and killing bacteria and fungi includes bringing a composition including a | 2021-12-23 |
20210393724 | MEDICINE FOR TREATMENT OF PSORIASIS AND PRODUCTION METHOD THEREOF - A medicine developed for treatment of psoriasis and production method thereof are disclosed. This medicine for treatment of psoriasis developed in the scope of the present invention comprises tallow, larch resin, beeswax, gum mastic, propolis, Alkanna tinctoria, alum and Juniper tar. The production method of the psoriasis medicine of the present invention includes the steps of: Melting the tallow at 300° C. by continuously mixing it with the beeswax, adding first the gum mastica and then the propolis to the obtained molten mixture, adding ground larch resin to the mixture together with alum, finally adding ground Alkanna tinctoria and juniper tar to the mixture, obtaining a homogenous mixture by means of continuous mixing, filtering the homogenous mixture, obtaining the medicine for treatment of psoriasis, which is the final product in the form an elute. | 2021-12-23 |
20210393725 | PUERARIA FLOWER EXTRACT RICH IN ISOFLAVONES AND A METHOD AND APPLICATION OF THE SAME - A method of preparing a | 2021-12-23 |
20210393726 | USE OF EXTRACT OF VEGETATION WATERS IN THE REGENERATION OF EPITHELIAL TISSUE - The present invention relates to a phytocomplex or natural concentrate, rich in polyphenol compounds, such as hydroxytyrosol and Oleuropein-aglycone di-aldehyde (3,4-DHPA-EDA), derived from the pressing waters of oil olives and/or from pomace from the olive grinding process, for use in the protection and/or regeneration of body tissues, in particular epithelial tissues. The present invention further relates to a composition comprising said concentrate and to the concentrate and/or composition formulated for oral use for example as a drink, pills or the like, or as a support for topical applications, and the use thereof in the protection and/or regeneration of body tissues, in particular of epithelial tissues. | 2021-12-23 |
20210393727 | COMPOSITION COMPRISING NIGELLA SATIVA OIL AND SURFACE-ACTIVE AGENTS - The invention provides a composition comprising oil obtained from | 2021-12-23 |
20210393728 | COMPOSITIONS OF COFFEE BEAN PRODUCTS, WHOLE HEMP PRODUCTS AND L-THEANINE - Disclosed are novel processing methods for green coffee beans, whole hemp plant, and L-theanine. The processing methods for the coffee beans and hemp plants are very similar. The coffee bean and hemp compositions formed are mixed together with L-theanine. | 2021-12-23 |
20210393729 | GRAPE EXTRACTS AND METHODS RELATING THERETO - Provided are liquid and powder grape extracts having elevated phenolic content. The extracts can be made from grape seeds, grape skins, or a combination thereof. In some instances, extracts may be blends of grape seed extracts and grape skin extracts. Methods of manufacturing such extracts area also provided. Such methods involve controlled temperature conditions to increase yield of phenolic compounds in the extracts. Methods of using the extraction for treating subjects are also provided, including treatment of cancer and end-organ damage relating to hypertension. | 2021-12-23 |
20210393730 | HERBAL COMPOSITION FOR REDUCING URIC ACID AND THE USE IN REDUCING URIC ACID, BODY FAT, AND BLOOD GLUCOSE THEREOF - Provided herein is a pharmaceutical composition comprising 1-2 part by weight of | 2021-12-23 |
20210393731 | COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTION - Compositions and methods for treating viral infection are disclosed. The compositions contain a combination of zinc and a cyclo(His-Pro), in effective amounts. The composition containing a combination of zinc and a cyclo(His-Pro) can be used to treat viral infections including SARS-CoV-2 infections in mammals. | 2021-12-23 |
20210393732 | Skin Lightening Formulations - Provided are pharmaceutical compositions for skin lightening, which are particularly useful in treating skin hyperpigmentation, together with methods for their use. The compositions comprise glutathione conjugated to a peptide having a sequence comprising PKEK and cysteamine or a pharmaceutical salt thereof. | 2021-12-23 |
20210393733 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE INTERMEDIATE BY ADDITION OF ACID AND USE THEREOF - Provided is a method for producing an antibody-drug conjugate intermediate by addition of acid. An acid additive is used to convert the monomethyl auristatin derivative into a salt thereof to participate in the reaction. The addition of the acid additive can significantly improve the yield of the final product. In addition, the low price of the acid additive greatly reduces the production cost of the final ADC product. Moreover, the method of the present invention adopts a one-step preparation process, in addition to a higher yield of the final product, not only reducing the cost of the consumables, labor, equipment, site, raw materials and the like in the production, but also greatly reducing the production of the waste liquid, and thus reducing production costs and improving production efficiency, and making the method suitable for industrial large-scale production. | 2021-12-23 |
20210393734 | THERAPEUTIC AGENT FOR ARTHRITIS - The present invention provides with a therapeutic agent for arthritis, which contains a low-molecular-weight FoxM1 inhibitor, e.g., thiostrepton, as an active ingredient. FoxM1 is expressed in an osteoclast progenitor that occurs specifically in an inflamed synovium in arthritis, and is not involved in the function of an osteoclast that is present in the bone marrow in a normal person and is involved in normal bone metabolism. Therefore, arthritis can be prevented and/or treated without any adverse side effect by using a FozM1 inhibitor. | 2021-12-23 |
20210393735 | PHARMACEUTICAL COMPOSITION COMPRISING TEICOPLANIN - The invention relates to a pharmaceutical composition or method for the treatment of microbial infections caused by bacteria, comprising administering to a patient separate therapeutically effective doses of teicoplanin or a pharmaceutically acceptable salt or prodrug thereof, wherein one or more loading doses of teicoplanin are administered, followed by administration of one or more maintenance doses of teicoplanin, wherein the amount of teicoplanin in each maintenance dose is half of the amount of each corresponding loading dose with about 10 to 14 hours intervals between each dose as well as pharmaceutical kit comprising separate pharmaceutical compositions with different therapeutically effective doses of teicoplanin. | 2021-12-23 |
20210393736 | NOVEL RECOMBINANT EXOSOME AND USE THEREOF - Provided is a recombinant exosome, and more specifically, to a recombinant exosome obtained from a eukaryotic cell transfected for the expression of a glucose transporter protein (GLUT) and a membrane fusogenic protein, and use thereof. | 2021-12-23 |
20210393737 | USE OF MAM POLYPEPTIDES FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS - The development of obesity is still increasing worldwide. Likewise, metabolic syndrome, which is a collection of obesity-associated disorders, is associated with development of cardiovascular diseases, insulin resistance, hepatic steatosis, certain types of cancer and type 2 diabetes. Recently, seven peptides were isolated from | 2021-12-23 |
20210393738 | Method For Treating Angiogenic Eye Disorders Using Vegf Antagonists - The present patent application provides methods for treating patients having angiogenic eye disorder by administering a VEGF antagonist, particularly an VEGF antagonist comprising the amino acid sequence of SEQ ID NO:1 in one or more treatment phases. | 2021-12-23 |
20210393739 | THERAPEUTIC AND COSMETIC USES AND APPLICATIONS OF CALRETICULIN - The invention relates to therapeutic and cosmetic uses of calreticulin including reducing eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion. | 2021-12-23 |
20210393740 | PTPRS AND PROTEOGLYCANS IN RHEUMATOID ARTHRITIS - Provided herein, inter alia, are pharmaceutical compositions methods thereof that include a first amount of a PTPRS de-clustering agent and a second amount of a TNF inhibitor or an IL-6 inhibitor in synergistic amounts. The synergistic combinations provide (a) amelioration of disease or one or more symptoms of disease or (b) delay of onset of disease or one or more symptoms of disease. | 2021-12-23 |
20210393741 | RECOMBINANT POLYPEPTIDES AND METHODS FOR USE IN THE TREATMENT OF CANCER - The present disclosure provides methods of preventing, delaying the progression of, treating or alleviating a symptom of, or otherwise ameliorating cancer in a subject by administering a recombinant polypeptide, an immune cell growth factor (e.g. FLT3L), a TNFa inhibitory agent (e.g. TNF alpha receptor), an IL-10 inhibitory agent (e.g. Interferon gamma) and/or an immunotherapy agent (e.g. anti-PD-1 antibody) to a subject in need thereof. | 2021-12-23 |
20210393742 | LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONIST IN COMBINATION WITH ANOTHER PHARMACOLOGICALLY ACTIVE AGENT - The instant disclosure provides a combination treatment, composition and kit comprising (a) a long-acting IL-15 receptor agonist and (b) one or more antibodies (mAb) targeting a tumor antigen, related methods of preparation and use, for example, in the treatment of conditions responsive to therapy effective to provide, for example, sustained immune activation and/or anti-tumor activity. | 2021-12-23 |
20210393743 | Use of IL13 for prevention and treatment of COVID19 - A method of use for prevention and treatment of COVID-19 using IL13 is described. | 2021-12-23 |
20210393744 | ACYLATED GLP-1 DERIVATIVE - Provided are a GLP-1(7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament. | 2021-12-23 |
20210393745 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES AND THEIR MEDICAL USE - This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to a novel Fc fragment, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions. | 2021-12-23 |
20210393746 | TREATMENT OF MYOCARDIAL INFARCTION - An injectable elastin-like recombinamer (ELR) hydrogel for use in a method of treating a mammal that has suffered a myocardial infarction to modulate the response of cardiac muscle damaged by the infarct is described. The hydrogel is injected into the cardiac muscle damaged by the infarct at least two days after the myocardial infarction, and results in clinically significant repair of cardiac muscle evidenced by at least one or more of reduced scarring, positive remodelling of the damaged muscle, restoring cardiac muscle function to a clinically significant extent after infarction an improvement in angiogenesis, or a decreased pro-inflammatory response in the infarct zone, and typically within 10, 20 or 30 days of administration. | 2021-12-23 |
20210393747 | RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE - Provided are a recombinant acid α-glucosidase and pharmaceutical composition comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa. Also provided herein are methods of producing, purifying, and formulating the recombinant acid α-glucosidase or pharmaceutical composition for administration to a subject and methods of treating a disease or disorder such as Pompe disease using the recombinant acid α-glucosidase or pharmaceutical composition. | 2021-12-23 |
20210393748 | NOVEL USES OF BOTULINUM NEUROTOXIN FOR TREATING LIPOEDEMA - This invention relates to novel uses of botulinum neurotoxin in treating a disease or condition associated with lipoedema, in particular uses of botulinum neurotoxin in treating pain associated with lipoedema. | 2021-12-23 |
20210393750 | INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF - Featured are a foodstuff containing an inter-alpha inhibitor protein (lαlp) (e.g., lαl, Pαl, a heavy chain (e.g., H1, H2, H3, H4, and/or H5), a light chain (e.g., bikunin), or a combination thereof), methods of preparing a food-stuff containing an lαlp, and methods of treating and/or reducing the likelihood of developing a disease or condition (e.g., a disease or condition characterized by inflammation and/or low levels of an lαlp) in a subject in need thereof by administering a composition or a foodstuff containing an lαlp. Also featured are methods of purifying an lλlp (e.g., lαl, Pαl, a heavy chain (e.g., H1, H2, H3, H4, and/or H5), a light chain (e.g., bikunin), or a combination thereof) from milk. | 2021-12-23 |
20210393751 | NOVEL PROTEIN MATERIAL - The invention relates to a protein material includes angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg, and cystatin and/or cystatin hydrolysate in the mass ratio to angiogenin and/or angiogenin hydrolysate of 0.003 to 0.6. | 2021-12-23 |
20210393752 | PEPTIDES, COMPOSITIONS AND VACCINES FOR TREATMENT OF MICROSATELLITE INSTABLITY HYPERMUTATED TUMORS AND METHODS OF USE THEREOF - Neoantigenic peptides useful for the treatment of MSI-H tumors, vaccines and composition comprising the peptides, and methods of inducing or enhancing an immune response and of treating MSI-H tumors are provided. | 2021-12-23 |
20210393753 | FGL2 NEUTRALING CELL THERAPY AND METHODS OF USE THEREOF - Provided herein is an FGL2 neutralization cell therapy comprising immune cells expressing a FGL2 neutralization construct. Further provided are methods for the treatment of cancer comprising administering the FGL2 neutralization cell therapy. | 2021-12-23 |
20210393754 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2021-12-23 |
20210393755 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN - The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of cancer or tumour diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal. | 2021-12-23 |
20210393756 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-12-23 |
20210393757 | Melanoma Canine Vaccine Compositions and Methods of Use Thereof - The present invention relates to compositions and methods for generating a nucleic acid delivery system comprising a nucleic acid sequence encoding a heterologous protein comprising a canine tumor-specific antigen (canine melanoma polyepitope (K9Melapoly)) and an inhibitor of an immuno-inhibitory pathway (HSV-1 gD). Additionally, the current invention includes compositions and methods of treating and/or preventing or immunizing a canine against melanoma, and methods of inducing an effector and memory T cell immune response in a canine administered the nucleic acid delivery system of the invention. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a canine as well as a protein expression system. | 2021-12-23 |
20210393758 | HYALURONIC ACID AS A NATURAL ADJUVANT FOR PROTEIN AND PEPTIDE-BASED VACCINES - Preparation of hyaluronic acid based vaccines and a prophylactic or therapeutic method includes vaccinating a patient with hyaluronic acid. | 2021-12-23 |
20210393759 | METHODS OF TREATING CANCER USING HETEROARYL-BIPHENYL AMIDE DERIVATIVES - Provided herein are methods of treating certain cancers comprising administering to the subject in need there of an effective amount of a compound of Formula (I) | 2021-12-23 |
20210393760 | PLASMODIUM WITH HISTAMINE RELEASING FACTOR (HRF) DEFICIENCY FOR USE AS A VACCINE - A method of generating an antibody and cellular immune response against a | 2021-12-23 |
20210393761 | ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF - This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of | 2021-12-23 |
20210393762 | BACTERIAL VACCINE COMPONENTS AND USES THEREOF - Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome. | 2021-12-23 |
20210393763 | NOVEL PNEUMOCOCCAL VACCINE FORMULATIONS - Immunogenic composition are provided comprising PnCo and/or GlpO polypeptides identified as being preferentially expressed during the virulent phase of an infection related to streptococcal bacteria. The compositions can be used for eliciting immune response against streptococcal infections, such as against infections caused by | 2021-12-23 |
20210393764 | Immunogenic Compositions for Use in Pneumococcal Vaccines - An object of the present invention is to provide immunogenic compositions for protection against | 2021-12-23 |
20210393765 | ROTAVIRUS VP7 FUSION PROTEINS AND ROTAVIRUS-LIKE PARTICLES COMPRISING THEM - Nucleic acids encoding rotavirus VP7 fusion proteins and rotavirus-like particle (RLPs) comprising the rotavirus VP7 fusion proteins are provided. Methods for rotavirus VP7 fusion protein and RLP production in plants are also described. The VP7 fusion protein comprises a first sequence encoding a 7-1a subdomain, a second sequence encoding a 7-2 domain and a third sequence encoding a 7-1b subdomain; wherein the sequence of the 7-2 domain is derived from a first rotavirus strain and the sequence of the 7-1a subdomain, the sequence of the 7-1b subdomain or the sequence of the 7-1a subdomain and the sequence of the 7-1b subdomain are derived from a second rotavirus strain. | 2021-12-23 |
20210393766 | Recombinant Modified Vaccinia Virus Ankara (MVA) Foot and Mouth Disease Virus (FMDV) Vaccine - The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against FMDV infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a FMDV protein. The invention also relates to products, methods and uses thereof, e.g., suitable to induce a protective immune response in a subject. | 2021-12-23 |
20210393767 | METHOD OF ENHANCING IMMUNE RESPONSE IN HOSTS - A method of enhancing immune response in hosts, including vaccinating the hosts with a immunogenic composition, so as to enhance antibody immune response and/or cellular immune response to an immunogen. The immunogenic composition includes the immunogen and an adjuvant additive. The adjuvant additive includes a receptor associated protein (RAP) having an amino acid sequence of SEQ ID NO:1 and/or a pseudomonas exotoxin A (PE) protein. | 2021-12-23 |
20210393768 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING VIRUS INFECTION - Disclosed herein are bacteria-based HIV MPER vaccine candidates, as well as bacteria-based candidates for other viruses and for bacteria. The HIV vaccine candidates express MPER-derived antigens on their surfaces using Gram autotransporters. The surface-expressed MPER antigens bind several different MPER-directed anti-HIV Broadly Neutralizing Monoclonal Antibodies. When the bacteria expressing the MPER-derived antigens on their surfaces are used to immunize mice they elicit the production of sera and vaginal wash material that bind the bacteria expressing the MPER antigens. At least one of the bacteria expressing MPER-derived antigens on their surfaces elicits the production of sera with anti-HIV neutralizing activity. Killed whole cell and live | 2021-12-23 |
20210393769 | CORONAVIRUS VACCINE AND METHODS OF USE THEREOF - An immunogenic composition effective for eliciting an immune response against cells that present coronavirus S protein and/or coronavirus M protein derived antigens on a virus-like-particle (VLP) system. In a method embodiment, the antigen presenting VLP is administered to a mammal, such as a human, to elicit an immune response against coronavirus S protein and/or coronavirus M protein. A preferred method embodiment may include at least one additional dose of immunogenic composition to enhance the immune response effectiveness of the coronavirus vaccine. | 2021-12-23 |
20210393770 | ADENOVIRAL VECTORS ENCODING HEPATITIS B VIRAL ANTIGENS FUSED TO HERPES VIRUS GLYCOPROTEIN D AND METHODS OF USING THE SAME - Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided. | 2021-12-23 |
20210393771 | VIRAL VACCINES FOR IN VIVO EXPRESSION OF A NUCLEIC ACIDS ENCODIND AN IMMUNOGENIC PEPTIDE AND METHODS OF USING THE SAME - The present disclosure provides particles for delivering a nucleic acid that encodes an immunogenic peptide in an antigen presenting cell. The disclosed particles can function as a vaccine and can be used to treat or prevent a viral or bacterial infection in a subject by expressing in vivo an immunogenic peptide, thereby stimulating the subject's immune system to attack the virus or bacteria that naturally express the immunogenic peptide. | 2021-12-23 |
20210393772 | ADJUVANT AND VACCINE COMPOSITIONS - Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin, polymer and one or more additives. The polymer is preferably polyacrylic acid-based. The additive is preferably one or more of a glycoside and a sterol. The method of preparation includes hydrating lecithin and a polymer in saline or water and mixing the lecithin and polymer to form the adjuvant. Additives can be included prior to or after hydration of the lecithin and polymer. | 2021-12-23 |
20210393773 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising bacterial strains for use as a vaccine adjuvant; for use in treating, preventing or delaying immunosenescence; or for use in enhancing a cell therapy, such as CAR-T. The invention also provides vaccine compositions comprising bacterial strains and one or more antigens. | 2021-12-23 |
20210393774 | COMPOSITIONS AND METHODS OF TREATING SARCOMA LUNG METASTASIS - A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/α4β1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing α4β1. | 2021-12-23 |
20210393775 | Daratumumab and Hyaluronidase for the Treatment of Multiple Myeloma - The present invention relates to methods of treating multiple myeloma using an approved drug product comprising daratumumab and hyaluronidase. Also described are drug products containing daratumumab and hyaluronidase, and methods of selling or offering for sale a drug product comprising daratumumab and hyaluronidase. | 2021-12-23 |
20210393776 | BISPECIFIC FAB FUSION PROTEINS COMPRISING A CD3-BINDING FAB FRAGMENT WITH N-TERMINAL FUSION TO A BINDING DOMAIN AND METHODS OF USE - The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner. | 2021-12-23 |
20210393777 | STABLE PREPARATION COMPRISING ANTI-PCSK9 ANTIBODY - The present invention provides a highly concentrated liquid formulation comprising an anti-PCSK9 (human proprotein convertase subtilisin/kexin 9) antibody. The formulation further comprises a buffer, a stabilizer and a surfactant. The liquid formulation disclosed has low viscosity, and the antibody is highly stable after several months of storage. | 2021-12-23 |
20210393778 | VEGF Antagonist Formulations - Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4. | 2021-12-23 |
20210393779 | ACTIVIN A ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF - The present invention provides novel pharmaceutical formulations comprising an antibody that specifically binds to human Activin A. The formulations may contain, in addition to an anti-Activin A antibody, a histidine buffer, an organic cosolvent, and a thermal stabilizer. The pharmaceutical formulations of the present invention exhibit a surprising degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress. | 2021-12-23 |
20210393780 | THERMOSENSITIVE HYDROGEL FOR CANCER THERAPEUTICS AND METHODS OF PREPARATION THEREOF - The present invention provides for thermosensitive hydrogel for cancer therapeutic and methods of preparation thereof. The invention represents an advancement in the field of cancer therapeutics and provides for a polymer-protein based thermosensitive hydrogel comprising polyvinyl alcohol, poloxamer 407 and bovine serum albumin. The thermosensitive hydrogel can be optionally be enriched with one or more additional component such as photothermal agents, photosensitizers, drugs and dyes. The invention also provides for a method of preparing the thermosensitive hydrogels. The hydrogels of the present invention are inexpensive, thermosensitive, has ability to effectuate sustained release of drugs and can be used for targeted delivery and dual-modality treatment. | 2021-12-23 |
20210393781 | SPIKY METAL ORGANIC FRAMEWORK, METHOD FOR FABRICATING THEREOF, AND KIT FOR TREATING CANCER - A spiky metal organic framework is provided in the present disclosure. The spiky metal organic framework is formed by a coordination reaction between at least one metal ion and an organic ligand, and includes a body and a plurality of spike-like structures. The body is a spherical shape, and a particle size of the body is 1 μm to 3 μm. The spike-like structures are distributed on a surface of the body, a diameter of each spike-like structure is 15 nm to 35 nm, and a length of each spike-like structure is 250 nm to 400 nm. | 2021-12-23 |
20210393782 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-12-23 |
20210393783 | AQUEOUS PHARMACEUTICAL FORMULATIONS - Provided are an aqueous pharmaceutical formulation comprising an antibody specific to the receptor of interleukin (IL)-6 (for example, Tocilizumab) and an effective amount of histidine for stabilizing the antibody. Said histidine is present in the aqueous pharmaceutical formulation at a concentration of 50 mM to 200 mM so as to achieve the stabilizing effect. | 2021-12-23 |
20210393784 | INJECTABLE CANNABINOID FORMULATIONS FOR TREATING PAIN - The present invention provides aqueous formulations containing at least one cannabinoid, such as, for example, tetrahydrocannabinol (THC), cannabidiol (CBD), and a sulfoalkyl ether cyclodextrin (SAE-CD). The liquid formulations are substantially clear, sterilizable, and chemically and physically stable. The liquid formulations do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The SAE-CD-containing formulation provides significant advantages over other cyclodextrin-containing formulations of cannabinoids. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of at least one cannabinoid suitable for administration by injection. An SAE-CD-containing formulation of at least one cannabinoid can be provided in liquid form or as a reconstitutable solid. Solutions can be made either dilatable or non-dilutable with water at room temperature or under conditions typically encountered in the clinic. | 2021-12-23 |
20210393785 | Nucleic acid nanocarrier drug and preparation method thereof - Disclosed are a nucleic acid nanocarrier drug and a preparation method thereof. The drug includes nucleic acid nanoparticles and a drug ingredient, the drug ingredient is loaded on the nucleic acid nanoparticles, and the drug ingredient is dihydroartemisinin, cisplatin, oxaliplatin, flavone or vincristine; the nucleic acid nanoparticles include a nucleic acid structureal domain, the nucleic acid structureal domain includes a sequence a, a sequence b, and a sequence c. The nucleic acid nanocarrier drug provided by the disclosure may have a better targeting property after the nucleic acid structureal domain thereof is modified by a target head, may deliver the drug ingredient stably, and has high reliability. | 2021-12-23 |
20210393786 | SMALL MOLECULE LIGAND-TARGETED DRUG CONJUGATES FOR ANTI-INFLUENZA CHEMOTHERAPY AND IMMUNOTHERAPY - Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients. | 2021-12-23 |
20210393787 | COMPOSITIONS AND METHODS FOR TREATING FRONTOTEMPORAL DEMENTIA - Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of frontotemportal dementia (FTD). Methods of treating frontotemporal dementia (FTD) and pharmaceutical compositions are also disclosed. | 2021-12-23 |
20210393788 | IGA FC-FOLATE CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER - IgA-based Fc-folate conjugates as a treatment for cancer are provided. The conjugates utilize only the Fc portion of IgA to target its receptor on neutrophils (FcαR1) to elicit antibody-dependent cellular-cytotoxicity (ADCC). | 2021-12-23 |
20210393789 | Sulfatase-Cleavable Linkers for Antibody-Drug Conjugates - The present disclosure provides antibody-drug conjugate structures, that include a cleavable linker having a sulfatase-cleavable moiety. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same. | 2021-12-23 |
20210393790 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE - A conjugation of a cytotoxic drug to a cell-binding molecule with a bis-linker (dual-linker) as shown in Formula (I). Bis-linkage methods of making a conjugate of a cytotoxic drug/molecule to a cell-binding agent in a specific manner are also described, as well as application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease. | 2021-12-23 |
20210393791 | COMBINATION TREATMENT WITH ANTI-CD123 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR - A composition including an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor can be used in therapy or as a medicament. The composition including the anti-CD123 antibody-drug conjugate and the poly ADP ribose (PARP) inhibitor can be used for treating cancer or for inducing cancer cell death in a population of cancer cells. Hematological cancers such as acute myeloid leukemia (AML) can be treated with the composition. Administering an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor is a method of treating cancer. Administering, to a population of cancer cells, an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor is a method for inducing cancer cell death. | 2021-12-23 |
20210393792 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2 - The present invention concerns antibody-conjugate having general structure (2): | 2021-12-23 |
20210393793 | AXL-SPECIFIC ANTIBODIES FOR TREATMENT OF NON-SMALL CELL LUNG CANCER - The present invention relates to immunoconjugates anti-AXL antibodies and compositions for treatment of non-small cell lung cancer. | 2021-12-23 |
20210393794 | SCREENING OF FIXED-POINT COUPLING SITES OF CYSTEINE-MODIFIED ANTIBODY-TOXIN CONJUGATE (TDC) - Disclosed in the present invention is a cysteine-modified antibody-toxin conjugate. The cysteine-modified antibody-toxin conjugate is characterized in that: the antibody is an antibody in which cysteine is inserted on a fixed point, and insertion sites of the cysteine comprising one or more of the following sites: a 110th site, a IIIth site and a 142th site of a light chain in a Kappa/λL light chain constant region, and a 254th site, a 255th site, a 258th, a 259th site, a 354th site, a 355th site, a 357th site, a 378th site, a 379th site, a 386th site, a 387th site or a 410th site of a heavy chain of a heavy chain constant region of an IgG antibody. | 2021-12-23 |
20210393795 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF - Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a —S(═O)(═N—)- functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor. | 2021-12-23 |
20210393796 | Methods for sustainable human cognitive enhancement - A method of achieving sustainable, general-purpose cognitive enhancement comprising administering a gene-editing endonuclease complexed with a neuron-targeting vector and a synthetic guide RNA to lower the population of 5-hydroxytryptamine 2A receptors in the brain. | 2021-12-23 |
20210393797 | VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS - The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules. | 2021-12-23 |
20210393798 | IRON OXIDE MESOPOROUS MICROPARTICLE DRUG CARRIER - A magnetic microparticle drug carrier comprising mesoporous iron oxide is described. The drug carrier has an average diameter in a range of 0.5-1.2 μm, a BET surface area ranging from 50-300 m | 2021-12-23 |
20210393799 | DENDRITIC POLYMERS COMPLEXED WITH IMMUNE CHECKPOINT INHIBITORS FOR ENHANCED CANCER IMMUNOTHERAPY - Described herein is a nanoparticle system including a multivalent nanoparticle core having a plurality of immune checkpoint inhibitors conjugated thereto. Also included are pharmaceutical compositions and methods of making the nanoparticle system. Further included are immunotherapy methods including administering the nanoparticle system to a subject in need thereof, such as a human cancer patient. | 2021-12-23 |
20210393800 | PREPARATION AND APPLICATION OF SUPRAMOLECULAR SELF-ASSEMBLED HYALURONIC ACID HYDROGEL - A hydrogel prepared through the supramolecular self-assembly of cyclodextrin and adamantane is described. The hydrogel can be filled with drugs and cells and used for various diseases. The hydrogel uses hyaluronic acid and thus can be applied to transdermal delivery, in vivo drug release, intractable disease treatment using stem cells, etc. | 2021-12-23 |
20210393801 | Adeno-Associated Virus Vector Delivery for Muscular Dystrophies - The disclosure provides method of treating muscular dystrophy in a subject in need comprising administering a gene therapy vector, such as adeno-associated virus (AAV) vector, expressing a miniaturized human micro-dystrophin gene in combination with a step of suppressing the subject's immune system. | 2021-12-23 |
20210393802 | GENE THERAPY FOR NEURONAL CEROID LIPOFUSCINOSES - Provided herein are methods and compositions for treatment of Batten disease. Such compositions include a recombinant adeno-associated virus (rAAV), said rAAV comprising an AAV capsid, and a vector genome packaged therein, said vector genome comprising (a) an AAV 5′ inverted terminal repeat (ITR) sequence; (b) a promoter; (c) a CLN2 coding sequence encoding a human TPP1; (d) an AAV 3′ ITR. Also provided herein are methods of treating Batten disease comprising administering to a subject in need thereof the rAAV described herein via more than one route. Also provide herein are pharmaceutical compositions comprising the rAAV described herein and related methods of treating Batten disease. | 2021-12-23 |
20210393803 | IMMUNOMODULATORY ONCOLYTIC ADENOVIRAL VECTORS, AND METHODS OF PRODUCTION AND USE THEREOF FOR TREATMENT OF CANCER - Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses. | 2021-12-23 |
20210393804 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING PAH GENE FUNCTION AND METHODS OF USE THEREOF - Provided herein are recombinant adeno-associated virus (rAAV) compositions that can restore phenylalanine hydroxylase (PAH) gene function in cells, and methods for using the same to treat diseases associated with reduction of PAH gene function (e.g., PKU). Also provided are nucleic acids, vectors, packaging systems, and methods for making the adeno-associated virus compositions. | 2021-12-23 |
20210393805 | PERFUSION-BASED DELIVERY OF RECOMBINANT AAV VECTORS FOR EXPRESSION OF SECRETED PROTEINS - In some aspects, the disclosure relates to methods and compositions for delivering a transgene to a subject. The disclosure is based, in part, on compositions (e.g., viral vectors, such as rAAV vectors) and methods of venous limb perfusion (VLP) that efficiently transduce muscle tissue and enhance serum concentrations of secreted transgenes. | 2021-12-23 |
20210393806 | CROSS-LINKED POLYMER MODIFIED NANOPARTICLES - Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease. | 2021-12-23 |
20210393807 | PHOTOACOUSTIC VOLTAGE-SENSITIVE DYES FOR IN VIVO IMAGING - Photoacoustic voltage dependent dyes and their use in measuring an electrophysiological activity in a subject in vivo are disclosed. | 2021-12-23 |
20210393808 | IMAGING OF METASTATIC OR RECURRENT CANCER - The present disclosure relates to methods of administering [ | 2021-12-23 |
20210393809 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS - The present invention relates to a compound of formula (1) (I), wherein Y | 2021-12-23 |
20210393810 | DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO A BETA PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF - The present disclosure provides dihydrazone compounds having high affinity to Aβ protein and Tau protein and derivatives thereof. The structure of the compounds is shown by formula (I) | 2021-12-23 |